• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lundbeck

43.24 DKK

-1.05 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.05 %
+4.49 %
+15.25 %
+0.19 %
-0.28 %
+10.31 %
+18.86 %
+12.40 %
+75.77 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Read more
Market cap
43.06B DKK
Turnover
22.45M DKK
Revenue
24.63B
EBIT %
21.42 %
P/E
13.43
Dividend yield-%
2.66 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
19/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

3/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press releaseyesterday

H. Lundbeck A/S: Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Lundbeck
Press release6/10/2026, 6:00 AM

H. Lundbeck A/S: Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Lundbeck
Press release6/4/2026, 8:00 PM

H. Lundbeck A/S: Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Lundbeck

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/3/2026, 12:00 PM

H. Lundbeck A/S: Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments

Lundbeck
Press release5/26/2026, 6:00 AM

H. Lundbeck A/S: Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Lundbeck
Press release5/18/2026, 8:03 AM

H. Lundbeck A/S: Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Lundbeck
Regulatory press release5/12/2026, 9:22 AM

Strong start to 2026: +21% CER revenue growth (+13% CER underlying)

Lundbeck
Regulatory press release5/12/2026, 9:15 AM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2026

Lundbeck
Press release4/19/2026, 1:00 PM

H. Lundbeck A/S: Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

Lundbeck
Press release4/13/2026, 7:00 AM

H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck
Regulatory press release3/18/2026, 12:00 PM

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office

Lundbeck
Press release3/16/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck
Press release3/10/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck appoints Chief AI Officer

Lundbeck
Regulatory press release3/9/2026, 9:33 AM

H. Lundbeck A/S: Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial

Lundbeck
Regulatory press release2/18/2026, 8:32 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Regulatory press release2/17/2026, 9:00 AM

To the shareholders of H. Lundbeck A/S

Lundbeck
Regulatory press release2/12/2026, 3:39 PM

H. Lundbeck A/S: Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

Lundbeck
Regulatory press release2/6/2026, 10:39 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Regulatory press release2/4/2026, 6:13 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Regulatory press release2/4/2026, 6:50 AM

H. Lundbeck A/S: Lundbeck Annual Report 2025

Lundbeck